SCHEDULE: RA Capital Increases Stake in Acrivon Therapeutics

RA Capital Management acquired 3,888,888 shares of Acrivon Therapeutics in an at-the-market offering for approximately $7 million.

Summary

• RA Capital Management, L.P. and its affiliates increased their beneficial ownership in Acrivon Therapeutics, Inc. to 12,284,906 shares.
• The acquisition occurred on April 22, 2026, through an at-the-market (ATM) offering.
• The purchase price was $1.80 per share, totaling $6,999,998.40.
• The reporting persons now hold a 28.8% stake in the company.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive event; while the dilution is a negative for existing shareholders, the strong backing from a major institutional investor provides a vote of confidence in the company's long-term prospects.

Positives

• Significant capital injection of approximately $7 million into the issuer via the ATM offering.
• Strong signal of confidence from a major institutional investor, RA Capital, by increasing their position.

Negatives

• The issuance of 3,888,888 new shares in the ATM offering results in dilution for existing shareholders.

Risks

• Market volatility associated with biotech equity offerings.
• Reliance on continued capital raises to fund clinical development and operations.

Future Outlook

The filing does not provide specific forward-looking guidance regarding the issuer's operations, but indicates the issuer is utilizing ATM offerings to raise capital.

Industry Context

StockSavvy.ai notes that biotech firms frequently utilize ATM offerings to extend cash runways. RA Capital's continued participation suggests they remain committed to the issuer's clinical pipeline despite the dilutive nature of the financing.

Comparison to Industry Standards

• Institutional participation in ATM offerings is a standard practice for small-cap biotech companies to maintain liquidity.
• A 28.8% ownership stake is a significant concentration, typical of venture-backed biotech firms where early investors maintain large positions through public offerings.

Stakeholder Impact

• Existing shareholders face dilution due to the issuance of new shares.
• The company gains approximately $7 million in working capital to support operations.

Next Steps

• Continued monitoring of RA Capital's holdings for further changes in position.

Key Dates

Recommendation

The increase in institutional ownership is a positive signal, but the dilution from the ATM offering suggests a need for caution regarding the company's cash burn and future financing requirements.

Keywords

Acrivon Therapeutics, RA Capital Management, Schedule 13D, Biotech, Equity Offering, Institutional Investor